Syndax Pharmaceuticals Inc
General ticker "SNDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B
Syndax Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -16.6%.
Estimated limits based on current volatility of 2.2%: low 12.77$, high 13.33$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [12.88$, 26.09$]
- 2024-12-30 to 2025-12-30 estimated range: [10.64$, 22.30$]
Financial Metrics affecting the SNDX estimates:
- Negative: Non-GAAP EPS, $ of -2.96 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -11.16 <= 2.35
- Positive: Interest expense per share, $ of 0 <= 0.14
- Negative: negative Net income
- Negative: -0.39 < Industry inventory ratio change (median), % of 0
- Positive: Inventory ratio change, % of -100 <= -1.03
Short-term SNDX quotes
Long-term SNDX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $139.71MM | $0.00MM | $0.00MM |
| Operating Expenses | $113.49MM | $151.76MM | $229.95MM |
| Operating Income | $26.22MM | $-151.76MM | $-229.95MM |
| Non-Operating Income | $-1.29MM | $2.42MM | $20.59MM |
| Interest Expense | $1.90MM | $3.14MM | $0.21MM |
| R&D Expense | $88.25MM | $118.50MM | $163.03MM |
| Income(Loss) | $24.93MM | $-149.34MM | $-209.36MM |
| Taxes | $0.00MM | $-5.59MM | $0.00MM |
| Profit(Loss) | $24.93MM | $-143.75MM | $-209.36MM |
| Stockholders Equity | $408.37MM | $467.45MM | $554.20MM |
| Inventory | $7.65MM | $4.25MM | $0.00MM |
| Assets | $449.66MM | $497.24MM | $612.88MM |
| Operating Cash Flow | $29.13MM | $-133.68MM | $-160.60MM |
| Capital expenditure | $0.13MM | $0.23MM | $0.00MM |
| Investing Cash Flow | $-40.87MM | $-186.19MM | $117.61MM |
| Financing Cash Flow | $118.46MM | $172.25MM | $264.13MM |
| Earnings Per Share* | $0.48 | $-2.37 | $-2.98 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.